Federal Register
Notice: FDA is making available a guidance for industry entitled Nonclinical Safety Evaluation of Drug or Biologic Combinations. This guidance provides recommendations on nonclinical approaches to support the clinical study and approval of fixed-dose combination products, co-packaged products, and some adjunctive therapies. To download this guidance, click here. To view this notice, click here.